Probiotics for Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

INTRODUCTION: Many patients with celiac disease (CD) experience persistent symptoms despite adhering to the gluten-free diet. Different studies have assessed the use of probiotics as an adjuvant treatment for CD. We performed a systematic review and meta-analysis to evaluate the efficacy of probiotics in improving gastrointestinal (GI) symptoms and quality of life (QOL) in patients with CD. METHODS: We searched EMBASE, MEDLINE, CINAHL, Web of Science, CENTRAL, and DARE databases up to February 2019 for randomized controlled trials (RCTs) evaluating probiotics compared with placebo for treating CD. We collected data on GI symptoms, QOL, adverse events, serum tumor necrosis factor-α, intestinal permeability, and microbiota composition. RESULTS: We screened 2,831 records and found that 7 articles describing 6 RCTs (n = 5,279 participants) were eligible for quantitative analysis. Probiotics improved GI symptoms when assessed by the GI Symptoms Rating Scale (mean difference symptom reduction: 228.7%; 95% confidence interval [CI] 243.96–213.52; P = 0.0002). There was no difference in GI symptoms after probiotics when different questionnaires were pooled. The levels of Bifidobacteria increased after probiotics (mean difference: 0.85 log colony-forming units (CFU) per gram; 95% CI 0.38–1.32 log CFU per gram; P = 0.0003). There were insufficient data on tumor necrosis factor-a levels or QOL for probiotics compared with placebo. No difference in adverse events was observed between probiotics and placebo. The overall certainty of the evidence ranged from very low to low. DISCUSSION: Probiotics may improve GI symptoms in patients with CD. High-quality clinical trials are needed to improve the certainty in the evidence (see Visual abstract, Supplementary Digital Content 2, http://links.lww.com/AJG/B595).

Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review

“…Although yet unproven, Lactobacillus and Bifidobacterium show promise in a variety of disorders through suppressing growth or invasion of pathogenic bacteria, improving intestinal barrier function, and modulating the immune system [ 77 , 78 , 79 , 80 ]. According to Gurung et al, both are among bacteria negatively associated with T2D together with Akkermansia , Bacteroides , Faecalibacterium , and Roseburia [ 2 ].…”

Probiotic supplement and gluten withdrawal in gluten allergy Patients may lead to gluten tolerance: first case report

“…There is no such case study till date which reports complete recovery of patient from celiac disease after administration of probiotic supplements along with GFD, but there are studies which indicate the positive prospects of probiotics in CD. [7][8][9] Primec et al in 2018 performed a double-blind placebo-controlled trial on 40 CD and 16 healthy children. CD patients were randomized to receive a mixture of two Bifidobacterium breve strains (DSM 16604 and DSM 24706) or placebo for a period of three months.…”

Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment

“…The efficacy of this approach was recently addressed in a meta-analysis that concluded that although probiotics may improve gastrointestinal symptoms in patients with CeD, there is significant heterogeneity between studies and high-quality clinical trials are needed to provide better evidence. 110 Thus, next-generation probiotics should be designed that target specific mechanisms in CeD pathophysiology. These therapies, specifically targeting pathogenic mechanisms or microbial alterations of interest in CeD, should be tested not only for better control of symptoms in patients who are nonresponders to the GFD, but also in primary prevention in at-risk individuals.…”